Placenta
Volume 29, Issue 6 , Pages 469-483 , June 2008

A Hypothesis for Preeclampsia: Adenosine and Inducible Nitric Oxide Synthase in Human Placental Microvascular Endothelium

,Accepted 12 February 2008.

References 

  1. San Martin R, Sobrevia L. Gestational diabetes and the adenosine/l-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta. 2006;27:1–10
  2. Myatt L. Placental adaptive responses and fetal programming. J Physiol. 2006;572:25–30
  3. Casanello P, Escudero C, Sobrevia L. Equilibrative nucleoside (ENTs) and cationic amino acid (CATs) transporters: implications in foetal endothelial dysfunction in human pregnancy diseases. Curr Vasc Pharmacol. 2007;5:69–84
  4. Schlembach D. Pre-eclampsia—still a disease of theories. Fukushima J Med Sci. 2003;49:69–115
  5. Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract. 2007;106:c72–c81
  6. Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T. Relation between adenosine and T-helper 1/T-helper 2 imbalance in women with preeclampsia. Obstet Gynecol. 2002;99:641–646
  7. Yoneyama Y, Sawa R, Suzuki S, Shin S, Power GG, Araki T. The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 1996;174:267–271
  8. Vasquez G, Sanhueza F, Vasquez R, Gonzalez M, San Martin R, Casanello P, et al. Role of adenosine transport in gestational diabetes-induced l-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J Physiol. 2004;560:111–122
  9. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflügers Arch. 2004;447:735–743
  10. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46:1077–1085
  11. Escudero C, Casanello P, Sobrevia L. Disminución del flujo placentario en preeclampsia severa: ¿está involucrada adenosina en éste fenómeno?. Bol Soc Esp Cienc Fisiol. 2007;9:6–9
  12. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991;12:301–308
  13. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental. Microcirculation. 2002;9:147–160
  14. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX–XIV
  15. Adamu YM, Salihu HM, Sathiakumar N, Alexander GR. Maternal mortality in Northern Nigeria: a population-based study. Eur J Obstet Gynecol Reprod Biol. 2003;109:153–159
  16. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, et al. World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol. 2006;194:921–931
  17. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799
  18. Mayhew TM, Ohadike C, Baker PN, Crocker IP, Mitchell C, Ong SS. Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta. 2003;24:219–226
  19. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG. 2006;113:580–589
  20. Mayhew TM, Manwani R, Ohadike C, Wijesekara J, Baker PN. The placenta in pre-eclampsia and intrauterine growth restriction: studies on exchange surface areas, diffusion distances and villous membrane diffusive conductances. Placenta. 2007;28:233–238
  21. Harrington K, Carpenter RG, Goldfrad C, Campbell S. Transvaginal Doppler ultrasound of the uteroplacental circulation in the early prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol. 1997;104:674–681
  22. Klockenbusch W, Goecke TW, Krüssel JS, Tutschek BA, Crombach G, Schrör K. Prostacyclin deficiency and reduced fetoplacental blood flow in pregnancy-induced hypertension and preeclampsia. Gynecol Obstet Invest. 2000;50:103–107
  23. Nakatsuka M, Takata M, Tada K, Asagiri K, Habara T, Noguchi S, et al. A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. J Ultrasound Med. 2002;21:831–836
  24. Gudnasson HM, Dubiel M, Gudmundsson S. Preeclampsia—abnormal uterine artery Doppler is related to recurrence of symptoms during the next pregnancy. J Perinat Med. 2004;32:400–403
  25. Aardema MW, Saro MC, Lander M, De Wolf BT, Oosterhof H, Aarnoudse JG. Second trimester Doppler ultrasound screening of the uterine arteries differentiates between subsequent normal and poor outcomes of hypertensive pregnancy: two different pathophysiological entities?. Clin Sci (Lond). 2004;106:377–382
  26. De Carolis S, Botta A, Garofalo S, Ferrazzani S, Martino C, Fatigante G, et al. Uterine artery velocity waveforms as predictors of pregnancy outcome in patients with antiphospholipid syndrome: a review. Ann N Y Acad Sci. 2007;1108:530–539
  27. Walters WA, Boura AL. Regulation of fetal vascular tone in the human placenta. Reprod Fertil Dev. 1991;3:475–481
  28. Ajne G, Ahlborg G, Wolff K, Nisell H. Contribution of endogenous endothelin-1 to basal vascular tone during normal pregnancy and preeclampsia. Am J Obstet Gynecol. 2005;193:234–240
  29. Wareing M, Bai X, Seghier F, Turner CM, Greenwood SL, Baker PN, et al. Expression and function of potassium channels in the human placental vasculature. Am J Physiol Regul Integr Comp Physiol. 2006;291:R437–R446
  30. Jewsbury S, Baker PN, Wareing M. Relaxation of human placental arteries and veins by ATP-sensitive potassium channel openers. Eur J Clin Invest. 2007;37:65–72
  31. Polat B, Tufan H, Danisman N. Vasorelaxant effect of levcromakalim on isolated umbilical arteries of preeclamptic women. Eur J Obstet Gynecol Reprod Biol. 2007;134:169–173
  32. King RG, Gude NM, Di Iulio JL, Brennecke SP. Regulation of human placental fetal vessel tone: role of nitric oxide. Reprod Fertil Dev. 1995;7:1407–1411
  33. Reid DL, Davidson SR, Phernetton TM, Rankin JH. Adenosine causes a biphasic response in the ovine fetal placental vasculature. J Dev Physiol. 1990;13:237–240
  34. Donoso MV, Lopez R, Miranda R, Briones R, Huidobro-Toro JP. A2B adenosine receptor mediates human chorionic vasoconstriction and signals through arachidonic acid cascade. Am J Physiol Heart Circ Physiol. 2005;288:H2439–H2449
  35. Omar HA, Rhodes LA, Ramirez R, Arsich J, Einzig S. Alteration of human placental vascular tone by antiarrhythmic medications in vitro. J Cardiovasc Electrophysiol. 1996;7:1197–1203
  36. Marzioni D, Tamagnone L, Capparuccia L, Marchini C, Amici A, Todros T, et al. Restricted innervation of uterus and placenta during pregnancy: evidence for a role of the repelling signal Semaphorin 3A. Dev Dyn. 2004;231:839–848
  37. Carbillon L, Uzan M, Uzan S. Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet Gynecol Surv. 2000;55:574–581
  38. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol. 2004;51:257–268
  39. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006;8:1–20
  40. Vatish M, Randeva HS, Grammatopoulos DK. Hormonal regulation of placental nitric oxide and pathogenesis of pre-eclampsia. Trends Mol Med. 2006;12:223–233
  41. Palmer LA, Semenza GL, Stoler MH, Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol. 1998;274:L212–L219
  42. Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Diab Rep. 2005;5:17–23
  43. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147:S193–S201
  44. Taylor BS, de Vera ME, Ganster RW, Wang Q, Shapiro RA, Morris SM, et al. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem. 1998;273:15148–15156
  45. Eissa NT, Haggerty CM, Palmer CD, Patton W, Moss J. Identification of residues critical for enzymatic activity in the domain encoded by exons 8 and 9 of the human inducible nitric oxide synthase. Am J Respir Cell Mol Biol. 2001;24:616–620
  46. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012
  47. Stuehr DJ. Enzymes of the l-arginine to nitric oxide pathway. J Nutr. 2004;134:2748S–2751S
  48. Terán E, Escudero C, Vivero S. Physiological change in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. Nitric Oxide. 2002;7:217–220
  49. Gladwin MT. Nitrite as an intrinsic signaling molecule. Nat Chem Biol. 2005;1:245–246
  50. Quintero M, Colombo SL, Godfrey A, Moncada S. Mitochondria as signaling organelles in the vascular endothelium. Proc Natl Acad Sci U S A. 2006;103:5379–5384
  51. Ahmad S, Hewett PW, Wang P, Al-Ani B, Cudmore M, Fujisawa T, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res. 2006;99:715–722
  52. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150–166
  53. Boveris A, Costa LE, Poderoso JJ, Carreras MC, Cadenas E. Regulation of mitochondrial respiration by oxygen and nitric oxide. Ann N Y Acad Sci. 2000;899:121–135
  54. Haynes V, Elfering SL, Squires RJ, Traaseth N, Solien J, Ettl A, et al. Mitochondrial nitric-oxide synthase: role in pathophysiology. IUBMB Life. 2003;55:599–603
  55. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A. 1992;89:7674–7677
  56. Cornwell TL, Ceaser EK, Li J, Marrs KL, Darley-Usmar VM, Patel RP. S-nitrosothiols inhibit uterine smooth muscle cell proliferation independent of metabolism to NO and cGMP formation. Am J Physiol Cell Physiol. 2003;284:C1516–C1524
  57. Zmijewski JW, Moellering DR, Le Goffe C, Landar A, Ramachandran A, Darley-Usmar VM. Oxidized LDL induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol. 2005;289:H852–H861
  58. Rassaf T, Feelisch M, Kelm M. Circulating NO pool: assessment of nitrite and nitroso species in blood and tissues. Free Radic Biol Med. 2004;36:413–422
  59. Yang Y, Loscalzo J. S-nitrosoprotein formation and localization in endothelial cells. Proc Natl Acad Sci U S A. 2005;102:117–122
  60. Terán E, Escudero C, Vivero S, Calle A, Molina G. NO in early pregnancy and development of preeclampsia. Hypertension. 2006;47:e17
  61. Ogonowski AA, Kaesemeyer WH, Jin L, Ganapathy V, Leibach FH, Caldwell RW. Effects of NO donors and synthase agonists on endothelial cell uptake of l-Arg and superoxide production. Am J Physiol Cell Physiol. 2000;278:C136–C143
  62. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol. 2000;57:68–74
  63. Casanello P, Sobrevia L. Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems y+/hCAT-1 and y+/hCAT-2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. Circ Res. 2002;91:127–134
  64. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev. 2003;83:183–252
  65. Sobrevia L, Mann GE. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol. 1997;82:423–452
  66. Flores C, Rojas S, Aguayo C, Parodi J, Mann G, Pearson JD, et al. Rapid stimulation of l-arginine transport by d-glucose involves p42/44(mapk) and nitric oxide in human umbilical vein endothelium. Circ Res. 2003;92:64–72
  67. Arancibia-Garavilla Y, Toledo F, Casanello P, Sobrevia L. Nitric oxide synthesis requires activity of the cationic and neutral amino acid transport system y+L in human umbilical vein endothelium. Exp Physiol. 2003;88:699–710
  68. Papageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. BJOG. 2005;112:703–709
  69. Teran E, Escudero C, Vivero S, Enriquez A, Calle A. Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia. Hypertens Pregnancy. 2004;23:303–308
  70. López-Jaramillo P, Narváez M, Calle A, Rivera J, Jácome P, Ruano C, et al. Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol. 1996;103:33–38
  71. Clark BA, Ludmir J, Epstein FH, Alvarez J, Tavara L, Bazul J, et al. Urinary cyclic GMP, endothelin, and prostaglandin E2 in normal pregnancy and preeclampsia. Am J Perinatol. 1997;14:559–562
  72. Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension. 2005;46:1123–1128
  73. Zamudio S. High-altitude hypoxia and preeclampsia. Front Biosci. 2007;12:2967–2977
  74. von Versen-Hoeynck FM, Powers RW. Maternal-fetal metabolism in normal pregnancy and preeclampsia. Front Biosci. 2007;12:2457–2470
  75. Lyall F, Young A, Greer IA. Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Am J Obstet Gynecol. 1995;173:714–718
  76. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod. 1996;1:107–116
  77. von Mandach U, Lauth D, Huch R. Maternal and fetal nitric oxide production in normal and abnormal pregnancy. J Matern Fetal Neonatal Med. 2003;13:22–27
  78. Parra MC, Lees C, Mann GE, Pearson JD, Nicolaides KH. Vasoactive mediator release by fetal endothelial cells in intrauterine growth restriction and preeclampsia. Am J Obstet Gynecol. 2001;184:497–502
  79. Akar F, Ark M, Uydeş BS, Soysal ME, Saraçoğlu F, Abacioğlu N, et al. Nitric oxide production by human umbilical vessels in severe pre-eclampsia. J Hypertens. 1994;12:1235–1241
  80. Beinder E, Mohaupt MG, Schlembach D, Fischer T, Sterzel RB, Lang N, et al. Nitric oxide synthase activity and Doppler parameters in the fetoplacental and uteroplacental circulation in preeclampsia. Hypertens Pregnancy. 1999;18:115–127
  81. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, et al. l-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension. 2004;43:614–622
  82. D'Aniello G, Tolino A, Fisher G. Plasma l-arginine is markedly reduced in pregnant women affected by preeclampsia. J Chromatogr B Biomed Sci Appl. 2001;753:427–431
  83. Kim YJ, Park HS, Lee HY, Ha EH, Suh SH, Oh SK, et al. Reduced l-arginine level and decreased placental eNOS activity in preeclampsia. Placenta. 2006;27:438–444
  84. Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?. Hypertension. 2007;49:90–95
  85. Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest. 2005;35:32–37
  86. Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M, Volpe A. l-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens Pregnancy. 2007;26:121–130
  87. Cynober LA. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition. 2002;18:761–766
  88. Closs EI. Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens. 2002;11:99–107
  89. Escudero C, González M, Vecchiola A, Casanello P, Sobrevia L. Adenosine reduces l-arginine transport and nitric oxide synthesis in human placental microvascular endothelium in preeclampsia. Acta Biomédica. 2006;77:60;[Abstract]
  90. Speake PF, Glazier JD, Ayuk PT, Reade M, Sibley CP, D'Souza SW. l-Arginine transport across the basal plasma membrane of the syncytiotrophoblast of the human placenta from normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2003;88:4287–4292
  91. Myatt L, Eis AL, Brockman DE, Greer IA, Lyall F. Endothelial nitric oxide synthase in placental villous tissue from normal, pre-eclamptic and intrauterine growth restricted pregnancies. Hum Reprod. 1997;12:167–172
  92. Ariel I, Hochberg A, Shochina M. Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease. J Clin Pathol. 1998;51:427–431
  93. Corthorn J, Germain AA, Chacón C, Rey S, Soto GX, Figueroa CD, et al. Expression of kallikrein, bradykinin b2 receptor, and endothelial nitric oxide synthase in placenta in normal gestation, preeclampsia, and placenta accreta. Endocrine. 2006;29:491–499
  94. Napolitano M, Miceli F, Calce A, Vacca A, Gulino A, Apa R, et al. Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas. J Clin Endocrinol Metab. 2000;85:2318–2323
  95. Orange SJ, Painter D, Horvath J, Yu B, Trent R, Hennessy A. Placental endothelial nitric oxide synthase localization and expression in normal human pregnancy and pre-eclampsia. Clin Exp Pharmacol Physiol. 2003;30:376–381
  96. Schiessl B, Mylonas I, Hantschmann P, Kuhn C, Schulze S, Kunze S, et al. Expression of endothelial NO synthase, inducible NO synthase, and estrogen receptors alpha and beta in placental tissue of normal, preeclamptic, and intrauterine growth-restricted pregnancies. J Histochem Cytochem. 2005;53:1441–1449
  97. Schonfelder G, Fuhr N, Hadzidiakos D, John M, Hopp H, Paul M. Preeclampsia is associated with loss of neuronal nitric oxide synthase expression in vascular smooth muscle cells of the human umbilical cord. Histopathology. 2004;44:116–128
  98. Mildenberger E, Biesel B, Siegel G, Versmold HT. Nitric oxide and endothelin in oxygen-dependent regulation of vascular tone of human umbilical vein. Am J Physiol Heart Circ Physiol. 2003;285:H1730–H1737
  99. Casanello P, Torres A, Sanhueza F, Gonzalez M, Farias M, Gallardo V, et al. Equilibrative nucleoside transporter 1 expression is downregulated by hypoxia in human umbilical vein endothelium. Circ Res. 2005;97:16–24
  100. Gorlach A. Control of adenosine transport by hypoxia. Circ Res. 2005;97:1–3
  101. Wyatt AW, Steinert JR, Wheeler-Jones CP, Morgan AJ, Sugden D, Pearson JD, et al. Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J. 2002;16:1584–1594
  102. González M, Flores C, Pearson JD, Casanello P, Sobrevia L. Cell signalling-mediating insulin increase of mRNA expression for cationic amino acid transporters-1 and -2 and membrane hyperpolarization in human umbilical vein endothelial cells. Pflugers Arch. 2004;448:383–394
  103. Guiet-Bara A, Ibrahim B, Leveteau J, Bara M. Calcium channels, potassium channels and membrane potential of smooth muscle cells of human allantochorial placental vessels. Bioelectrochem Bioenerg. 1999;48:407–413
  104. Hampl V, Bíbová J, Stranák Z, Wu X, Michelakis ED, Hashimoto K, et al. Hypoxic fetoplacental vasoconstriction in humans is mediated by potassium channel inhibition. Am J Physiol Heart Circ Physiol. 2002;283:H2440–H2249
  105. Sand A, Andersson E, Fried G. Nitric oxide donors mediate vasodilation in human placental arteries partly through a direct effect on potassium channels. Placenta. 2006;27:181–190
  106. Fujita A, Kurachi Y. Molecular aspects of ATP-sensitive K+ channels in the cardiovascular system and K+ channel openers. Pharmacol Ther. 2000;85:39–53
  107. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang SC, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A. 1993;90:3491–3495
  108. Chartrain NA, Geller DA, Koty PP, Sitrin NF, Nussler AK, Hoffman EP, et al. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J Biol Chem. 1994;269:6765–6772
  109. Venema RC, Sayegh HS, Kent JD, Harrison DG. Identification, characterization, and comparison of the calmodulin-binding domains of the endothelial and inducible nitric oxide synthases. J Biol Chem. 1996;271:6435–6440
  110. Musial A, Eissa NT. Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J Biol Chem. 2001;276:24268–24273
  111. Galijasevic S, Saed GM, Diamond MP, Abu-Soud HM. Myeloperoxidase up-regulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition. Proc Natl Acad Sci U S A. 2003;100:14766–14771
  112. Kleinert H, Schwarz PM, Forstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem. 2003;384:1343–1364
  113. Zhang W, Kuncewicz T, Yu ZY, Zou L, Xu X, Kone BC. Protein–protein interactions involving inducible nitric oxide synthase. Acta Physiol Scand. 2003;179:137–142
  114. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein–Barr virus reactivation. Cell. 1994;79:1137–1146
  115. Buchwalow IB, Podzuweit T, Bocker W, Samoilova VE, Thomas S, Wellner M, et al. Vascular smooth muscle and nitric oxide synthase. FASEB J. 2002;16:500–508
  116. Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, Furneaux H, Levy AP, Förstermann U, et al. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem. 2000;275:26040–26049
  117. Kone BC, Kuncewicz T, Zhang W, Yu ZY. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol. 2003;285:F178–F190
  118. Cooke CL, Davidge ST. Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol. 2002;282:C395–C402
  119. Hattori Y, Kasai K, Gross SS. NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res. 2004;63:31–40
  120. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol. 2004;500:255–266
  121. Chan GC, Fish JE, Mawji IA, Leung DD, Rachlis AC, Marsden PA. Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells. J Immunol. 2005;175:3846–3861
  122. Asano K, Chee CB, Gaston B, Lilly CM, Gerard C, Drazen JM, et al. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A. 1994;91:10089–10093
  123. Binion DG, Rafiee P, Ramanujam KS, Fu S, Fisher PJ, Rivera MT, et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med. 2000;29:881–888
  124. Rafiee P, Johnson CP, Li MS, Ogawa H, Heidemann J, Fisher PJ, et al. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem. 2002;277:35605–35615
  125. Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension. 1996;28:488–493
  126. Faxen M, Nisell H, Kublickiene KR. Altered mRNA expression of ecNOS and iNOS in myometrium and placenta from women with preeclampsia. Arch Gynecol Obstet. 2001;265:45–50
  127. Tranquilli AL, Giannubilo SR, Tedeschi E, Bezzeccheri V, Suzuki H, Menegazzi M. Placental expression of nitric oxide synthase during HELLP syndrome: the correlation with maternal-fetal Doppler velocimetry. Acta Obstet Gynecol Scand. 2005;84:849–853
  128. Schiessl B, Mylonas I, Kuhn C, Kunze S, Schulze S, Friese K, et al. Expression of estrogen receptor-alpha, estrogen receptor-beta and placental endothelial and inducible NO synthase in intrauterine growth-restricted and normal placentals. Arch Med Res. 2006;37:967–975
  129. Tan C, Mui A, Dedhar S. Integrin-linked kinase regulates inducible nitric oxide synthase and cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J Biol Chem. 2002;277:3109–3116
  130. Chu SC, Marks-Konczalik J, Wu HP, Banks TC, Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem Biophys Res Commun. 1998;248:871–878
  131. Jana M, Anderson JA, Saha RN, Liu X, Pahan K. Regulation of inducible nitric oxide synthase in proinflammatory cytokine-stimulated human primary astrocytes. Free Radic Biol Med. 2005;38:655–664
  132. Chang K, Lee SJ, Cheong I, Billiar TR, Chung HT, Han JA, et al. Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IkappaB. Exp Mol Med. 2004;36:311–324
  133. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci U S A. 2001;98:8638–8643
  134. Takacs P, Kauma SW, Sholley MM, Walsh SW, Dinsmoor MJ, Green K. Increased circulating lipid peroxides in severe preeclampsia activate NF-kappaB and upregulate ICAM-1 in vascular endothelial cells. FASEB J. 2001;15:279–281
  135. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632–1639
  136. Aban M, Cinel L, Arslan M, Dilek U, Kaplanoglu M, Arpaci R, et al. Expression of nuclear factor-kappa B and placental apoptosis in pregnancies complicated with intrauterine growth restriction and preeclampsia: an immunohistochemical study. Tohoku J Exp Med. 2004;204:195–202
  137. McCracken SA, Drury CL, Lee HS, Morris JM. Pregnancy is associated with suppression of the nuclear factor kappaB/IkappaB activation pathway in peripheral blood mononuclear cells. J Reprod Immunol. 2003;58:27–47
  138. Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Charnock-Jones DS, Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol. 2007;170:1511–1520
  139. Sobrevia L, Yudilevich DL, Mann GE. Activation of A2-purinoceptors by adenosine stimulates l-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J Physiol. 1997;499:135–140
  140. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005;46:1243–1249
  141. Zimmermann H, Braun N, Kegel B, Heine P. New insights into molecular structure and function of ectonucleotidases in the nervous system. Neurochem Int. 1998;32:421–425
  142. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552
  143. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal. 2003;15:813–827
  144. Desai A, Victor-Vega C, Gadangi S, Montesinos MC, Chu CC, Cronstein BN. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol Pharmacol. 2005;67:1406–1413
  145. Broch OJ, Ueland PM. Regional and subcellular distribution of S-adenosylhomocysteine hydrolase in the adult rat brain. J Neurochem. 1980;35:484–488
  146. Olah ME, Stiles GL. The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther. 2000;85:55–75
  147. Freissmuth M, Selzer E, Schutz W. Interactions of purified bovine brain A1-adenosine receptors with G-proteins. Reciprocal modulation of agonist and antagonist binding. Biochem J. 1991;275:651–656
  148. Akbar M, Okajima F, Tomura H, Shimegi S, Kondo Y. A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol Pharmacol. 1994;45:1036–1042
  149. Jockers R, Linder ME, Hohenegger M, Nanoff C, Bertin B, Strosberg AD, et al. Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994;269:32077–32084
  150. Antonio L, Trincavelli ML. Adenosine: old passion, new perspectives. Ital J Biochem. 2004;53:141–147
  151. Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol. 2003;65:493–501
  152. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Voyno-Yasenetskaya T, et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res. 2002;90:531–538
  153. Feoktistov I, Ryzhov S, Zhong H, Goldstein AE, Matafonov A, Zeng D, et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension. 2004;44:649–654
  154. Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest Ophthalmol Vis Sci. 2001;42:2068–2073
  155. Richard LF, Dahms TE, Webster RO. Adenosine prevents permeability increase in oxidant-injured endothelial monolayers. Am J Physiol. 1998;274:H35–H42
  156. Yoneyama Y, Suzuki S, Sawa R, Kiyokawa Y, Power GG, Araki T. Plasma adenosine levels and P-selectin expression on platelets in preeclampsia. Obstet Gynecol. 2001;97:366–370
  157. Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, Araki T. Increased plasma adenosine concentrations and the severity of preeclampsia. Obstet Gynecol. 2002;100:1266–1270
  158. Suzuki S, Yoneyama Y, Sawa R, Otsubo Y, Takeuchi T, Araki T. Relation between serum uric acid and plasma adenosine levels in women with preeclampsia. Gynecol Obstet Invest. 2001;51:169–172
  159. Takeuchi T, Yoneyama Y, Suzuki S, Sawa R, Otsubo Y, Araki T. Regulation of platelet aggregation in vitro by plasma adenosine in preeclampsia. Gynecol Obstet Invest. 2001;51:36–39
  160. Karabulut AB, Kafkasli A, Burak F, Gozukara EM. Maternal and fetal plasma adenosine deaminase, xanthine oxidase and malondialdehyde levels in pre-eclampsia. Cell Biochem Funct. 2005;23:279–283
  161. Maguire MH, Szabo I, Valko IE, Finley BE, Bennett TL. Simultaneous measurement of adenosine and hypoxanthine in human umbilical cord plasma using reversed-phase high-performance liquid chromatography with photodiode-array detection and on-line validation of peak purity. J Chromatogr B Biomed Sci Appl. 1998;707:33–41
  162. Kafkasli A, Karabulut AB, Atmaca R, Laurini R. Clinical correlation between adenosine deaminase activity and pre-eclampsia severity. J Int Med Res. 2006;34:247–255
  163. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoz I, Martínez-Picado J, et al. Cell entry and export of nucleoside analogues. Virus Res. 2005;107:151–164
  164. Aguayo C, Casado J, Gonzalez M, Pearson JD, Martin RS, Casanello P, et al. Equilibrative nucleoside transporter 2 is expressed in human umbilical vein endothelium, but is not involved in the inhibition of adenosine transport induced by hyperglycaemia. Placenta. 2005;26:641–653
  165. Farías M, San Martín R, Puebla C, Pearson JD, Casado JF, Pastor-Anglada M, et al. Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006;208:451–460
  166. Munoz G, San Martin R, Farias M, Cea L, Vecchiola A, Casanello P, et al. Insulin restores glucose inhibition of adenosine transport by increasing the expression and activity of the equilibrative nucleoside transporter 2 in human umbilical vein endothelium. J Cell Physiol. 2006;209:826–835
  167. Aguayo C, Sobrevia L. Nitric oxide, cGMP and cAMP modulate nitrobenzylthioinosine-sensitive adenosine transport in human umbilical artery smooth muscle cells from subjects with gestational diabetes. Exp Physiol. 2000;85:399–409
  168. Aguayo C, Flores C, Parodi J, Rojas R, Mann GE, Pearson JD, et al. Modulation of adenosine transport by insulin in human umbilical artery smooth muscle cells from normal or gestational diabetic pregnancies. J Physiol. 2001;534:243–254
  169. Barros LF, Bustamante JC, Yudilevich DL, Jarvis SM. Adenosine transport and nitrobenzylthioinosine binding in human placental membrane vesicles from brush-border and basal sides of the trophoblast. J Membr Biol. 1991;119:151–161
  170. Barros LF, Yudilevich DL, Jarvis SM, Beaumont N, Young JD, Baldwin SA. Immunolocalisation of nucleoside transporters in human placental trophoblast and endothelial cells: evidence for multiple transporter isoforms. Pflugers Arch. 1995;429:349–394
  171. Escudero C, Krause B, Casanello P, Sobrevia L. Preeclampsia is associated with increased adenosine transport via the human equilibrative nucleoside transporter 2 in placental microvascular endothelial cells. Placenta. 2007;28:A64;[Abstract]
  172. Escudero C, Casanello P, Sobrevia L. Expression and activity of hNET1 and hENT2 are regulated by adenosine receptor in placenta microvascular endothelium from preeclampsia. Pediatr Res. 2007;62:385;[Abstract]
  173. Devés R, Boyd CA. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev. 1998;78:487–545
  174. Schocken DD, Schneider MN. Use of multiple radioligands to characterize adenosine receptors in human placenta. Placenta. 1986;7:339–348
  175. Reviriego J, Alonso MJ, Ibanez C, Marin J. Action of adenosine and characterization of adenosine receptors in human placental vasculature. Gen Pharmacol. 1990;21:227–233
  176. Read MA, Boura AL, Walters WA. Vascular actions of purines in the foetal circulation of the human placenta. Br J Pharmacol. 1993;110:454–460
  177. Puffinbarger NK, Hansen KR, Resta R, Laurent AB, Knudsen TB, Madara JL, et al. Production and characterization of multiple antigenic peptide antibodies to the adenosine A2b receptor. Mol Pharmacol. 1995;47:1126–1132
  178. Brodie C, Blumberg PM, Jacobson KA. Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett. 1998;429:139–142
  179. Sands WA, Martin AF, Strong EW, Palmer TM. Specific inhibition of nuclear factor-kappaB-dependent inflammatory responses by cell type-specific mechanisms upon A2A adenosine receptor gene transfer. Mol Pharmacol. 2004;66:1147–1159
  180. Lee JK, Won JS, Singh AK, Singh I. Adenosine kinase inhibitor attenuates the expression of inducible nitric oxide synthase in glial cells. Neuropharmacology. 2005;48:151–160
  181. Apasov S, Chen JF, Smith P, Sitkovsky M. A(2A) receptor dependent and A(2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood. 2000;95:3859–3867
  182. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916–920
  183. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol. 2004;173:21–24
  184. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996;270:C522–C529
  185. Gsandtner I, Charalambous C, Stefan E, Ogris E, Freissmuth M, Zezula J. Heterotrimeric G protein-independent signaling of a G protein-coupled receptor. Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A adenosine receptor is necessary for sustained activation of the ERK/MAP kinase pathway. J Biol Chem. 2005;280:31898–31905
  186. Escudero C, Casanello P, Sobrevia L. Adenosine receptor A2A stimulation decreases nitric oxide synthesis in placental microvascular endotelial cells from women with preeclampsia and intrauterine growth restriction. Early Hum Dev. 2006;82:496;[Abstract]
  187. Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod. 2001;64:1033–1040
  188. Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem. 2007;109:257–265
  189. Risau W, Esser S, Engelhardt B. Differentiation of blood–brain barrier endothelial cells. Pathol Biol (Paris). 1998;46:171–175
  190. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovasc Surg. 2005;39:293–306
  191. Auchampach JA. Adenosine receptors and angiogenesis. Circ Res. 2007;101:1075–1077
  192. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14:1315–1323
  193. Clark AN, Youkey R, Liu X, Jia L, Blatt R, Day YJ, et al. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res. 2007;101:1130–1138
  194. Gigante B, Morlino G, Gentile MT, Persico MG, De Falco S. Plgf−/−eNos−/− mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. FASEB J. 2006;20:970–972
  195. González C, Parra A, Ramírez-Peredo J, García C, Rivera JC, Macotela Y, et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest. 2007;87:1009–1017
  196. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol. 2001;159:993–1008
  197. Chang CC, Chang TY, Yu CH, Tsai ML. Induction of VE-cadherin in rat placental trophoblasts by VEGF through a NO-dependent pathway. Placenta. 2005;26:234–241
  198. Steinert JR, Wyatt AW, Poston L, Jacob R, Mann GE. Preeclampsia is associated with altered Ca2+ regulation and NO production in human fetal venous endothelial cells. FASEB J. 2002;16:721–723
  199. Donker RB, Asgeirsdóttir SA, Gerbens F, van Pampus MG, Kallenberg CG, te Meerman GJ, et al. Plasma factors in severe early-onset preeclampsia do not substantially alter endothelial gene expression in vitro. J Soc Gynecol Investig. 2005;12:98–106
  200. Wang X, Athayde N, Trudinger B. Maternal plasma from pregnant women with umbilical placental vascular disease does not affect endothelial cell mRNA expression of nitric oxide synthase. J Soc Gynecol Investig. 2004;11:149–153

PII: S0143-4004(08)00074-X

doi: 10.1016/j.placenta.2008.02.008

Placenta
Volume 29, Issue 6 , Pages 469-483 , June 2008

Article Tools

* Image Usage & Resolution